Literature DB >> 12076996

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Claudia F Lucchinetti1, Raul N Mandler, Dorian McGavern, Wolfgang Bruck, Gerald Gleich, Richard M Ransohoff, Corinna Trebst, Brian Weinshenker, Dean Wingerchuk, Joseph E Parisi, Hans Lassmann.   

Abstract

Devic's disease [neuromyelitis optica (NMO)] is an idiopathic inflammatory demyelinating disease of the CNS, characterized by attacks of optic neuritis and myelitis. The mechanisms that result in selective localization of inflammatory demyelinating lesions to the optic nerves and spinal cord are unknown. Serological and clinical evidence of B cell autoimmunity has been observed in a high proportion of patients with NMO. The purpose of this study was to investigate the importance of humoral mechanisms, including complement activation, in producing the necrotizing demyelination seen in the spinal cord and optic nerves. Eighty-two lesions were examined from nine autopsy cases of clinically confirmed Devic's disease. Demyelinating activity in the lesions was immunocytochemically classified as early active (21 lesions), late active (18 lesions), inactive (35 lesions) or remyelinating (eight lesions) by examining the antigenic profile of myelin degradation products within macrophages. The pathology of the lesions was analysed using a broad spectrum of immunological and neurobiological markers, and lesions were defined on the basis of myelin protein loss, the geography and extension of plaques, the patterns of oligodendrocyte destruction and the immunopathological evidence of complement activation. The pathology was identical in all nine patients. Extensive demyelination was present across multiple spinal cord levels, associated with cavitation, necrosis and acute axonal pathology (spheroids), in both grey and white matter. There was a pronounced loss of oligodendrocytes within the lesions. The inflammatory infiltrates in active lesions were characterized by extensive macrophage infiltration associated with large numbers of perivascular granulocytes and eosinophils and rare CD3(+) and CD8(+) T cells. There was a pronounced perivascular deposition of immunoglobulins (mainly IgM) and complement C9neo antigen in active lesions associated with prominent vascular fibrosis and hyalinization in both active and inactive lesions. The extent of complement activation, eosinophilic infiltration and vascular fibrosis observed in the Devic NMO cases is more prominent compared with that in prototypic multiple sclerosis, and supports a role for humoral immunity in the pathogenesis of NMO. Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076996      PMCID: PMC5444467          DOI: 10.1093/brain/awf151

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  48 in total

Review 1.  Complement as a promiscuous signal transduction device.

Authors:  S S Asghar; M C Pasch
Journal:  Lab Invest       Date:  1998-10       Impact factor: 5.662

2.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

3.  Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjögren's syndrome.

Authors:  Y T Konttinen; E Kinnunen; M von Bonsdorff; P Lillqvist; I Immonen; V Bergroth; M Segerberg-Konttinen; C Friman
Journal:  Arthritis Rheum       Date:  1987-03

4.  Multiple sclerosis associated with eosinophilic vasculitis, pericarditis, and hypocomplementemia.

Authors:  K Tanphaichitr
Journal:  Arch Neurol       Date:  1980-05

5.  Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.

Authors:  C G Haase; S Schmidt
Journal:  Neurosci Lett       Date:  2001-07-13       Impact factor: 3.046

6.  Devic's syndrome and systemic lupus erythematosus: a case report with necropsy.

Authors:  E L Kinney; R L Berdoff; N S Rao; L M Fox
Journal:  Arch Neurol       Date:  1979-10

7.  Devic's neuromyelitis optica: a clinicopathological study of 8 patients.

Authors:  R N Mandler; L E Davis; D R Jeffery; M Kornfeld
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

8.  A case of neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus. Clinicopathologic report and review of the literature.

Authors:  R S April; E Vansonnenberg
Journal:  Neurology       Date:  1976-11       Impact factor: 9.910

9.  Activated eosinophils are the major source of Th2-associated cytokines in the schistosome granuloma.

Authors:  C A Rumbley; H Sugaya; S A Zekavat; M El Refaei; P J Perrin; S M Phillips
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

10.  Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.

Authors:  P D Ponath; S Qin; T W Post; J Wang; L Wu; N P Gerard; W Newman; C Gerard; C R Mackay
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  346 in total

Review 1.  A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.

Authors:  Christopher Eckstein; Shiv Saidha; Michael Levy
Journal:  J Neurol       Date:  2011-09-20       Impact factor: 4.849

Review 2.  Recent neuropathological findings in MS--implications for diagnosis and therapy.

Authors:  Hans Lassmann
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

3.  Illuminating neuromyelitis optica pathogenesis.

Authors:  Richard M Ransohoff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

4.  Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain.

Authors:  Samira Saadoun; Patrick Waters; Claire MacDonald; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Ann Neurol       Date:  2012-02-28       Impact factor: 10.422

Review 5.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

6.  T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.

Authors:  Robert C Axtell; Brigit A de Jong; Katia Boniface; Laura F van der Voort; Roopa Bhat; Patrizia De Sarno; Rodrigo Naves; May Han; Franklin Zhong; Jim G Castellanos; Robert Mair; Athena Christakos; Ilan Kolkowitz; Liat Katz; Joep Killestein; Chris H Polman; René de Waal Malefyt; Lawrence Steinman; Chander Raman
Journal:  Nat Med       Date:  2010-03-28       Impact factor: 53.440

7.  Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.

Authors:  Gregory F Wu; Chelsea R Parker Harp; Kenneth S Shindler
Journal:  Curr Immunol Rev       Date:  2015

8.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

9.  Review of Animal Models of Neuromyelitis Optica.

Authors:  Melina V Jones; Nicolas Collongues; Jerome de Seze; Makoto Kinoshita; Yuji Nakatsuji; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

10.  Visualization of inflammation and demyelination in 2D2 transgenic mice with rodent MRI.

Authors:  Jordan C Bell; Qingwei Liu; Yan Gan; Qiang Liu; Yaou Liu; Fu-Dong Shi; Gregory H Turner
Journal:  J Neuroimmunol       Date:  2013-09-18       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.